The DOI matches its Crossref record.
PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE
Abstract
Laboratory-attenuated strains of each of the four dengue serotypes previously tested as monovalent vaccines in volunteers were combined and tested for immunogenicity, safety, and reactogenicity in 16 dosage combinations. Tetravalent vaccines made using combinations of high (10 5–6 plaque-forming units [PFU]/dose) or low (10 3.5–4.5 PFU/dose) dosage formulations of each of the four viruses were inoculated in 64 flavivirus non-immune adult volunteers to determine which, if any, formulation raised neutralizing antibodies in at least 75% of volunteers to at least three of four dengue serotypes following one or two inoculations. Such formulations, if safe and sufficiently non-reactogenic, would be considered for an expanded Phase II trial in the future. Formulations 1–15 were each inoculated into three or four volunteers (total = 54) on days 0 and 28. Formulation 16 was tested in 10 volunteers, five volunteers inoculated on days 0 and 30, one volunteer on days 0 and 120, and four volunteers on days 0, 30, and 120. Blood was drawn for serologic assays immediately before and one month after each vaccination, and for viremia assay on day 10 after each vaccination. The 16 formulations were safe, but variably reactogenic after the first vaccination, and nearly non-reactogenic after the second and third vaccinations. Reactogenicity was positively correlated with immunogenicity. Similar proportions of volunteers seroconverted to dengue-1 (69%), dengue-2 (78%), and dengue-3 (69%), but significantly fewer volunteers seroconverted to dengue-4 (38%). The geometric mean 50% plaque reduction neutralization test titers in persons who seroconverted were significantly higher to dengue-1 (1:94) than to dengue-2 (1:15), dengue-3 (1:10), and dengue-4 (1:2). Seven formulations met the serologic criteria required for an expanded trial, and three of these were sufficiently attenuated clinically to justify further testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dengue: a continuing global threat
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., et al. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2460 · Cited by 2,082
Guzman, M. G., Gubler, D. J., Izquierdo, A., Martinez, E., & Halstead, S. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.55 · Cited by 762
Prospects for a dengue virus vaccine
Whitehead, S. S., Blaney, J. E., Durbin, A. P., & Murphy, B. R. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1690 · Cited by 623
A review of Dengvaxia®: development to deployment
Thomas, S. J., & Yoon, I.-K. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1658503 · Cited by 331
Metadata
- Authors
- EDELMAN, R., WASSERMAN, S. S., BODISON, S. A., PUTNAK, R. J., ECKELS, K. H., TANG, D., KANESA-THASAN, N., VAUGHN, D. W., INNIS, B. L., & SUN, W.
- Venue
- The American Journal of Tropical Medicine and Hygiene
- Published
- 2003-12
- Volume
- 69
- Issue
- 6_suppl
- Pages
- 48-60
- ISSN
- 0002-9637 (ISSN-L)
- OpenAlex
- W2124109048
- Cited by
- 168
- References
- 0
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE. https://app.cochat.ai/papers/10.4269/ajtmh.2003.69.48
- The paper
- EDELMAN, R., WASSERMAN, S. S., BODISON, S. A., PUTNAK, R. J., ECKELS, K. H., TANG, D., KANESA-THASAN, N., VAUGHN, D. W., INNIS, B. L., & SUN, W. (2003). PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.2003.69.48
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.